SciSparc Ltd. is shifting focus to Agentic AI technologies, targeting cybersecurity and finance opportunities for future growth.
Quiver AI Summary
SciSparc Ltd. has announced a strategic pivot towards Agentic AI-powered technologies, particularly focusing on applications in cybersecurity and finance. This decision follows their prior moves to target the Agentic AI market and establish a Scientific Advisory Board for AI and Cybersecurity. The company plans to explore technologies and business opportunities within the Agentic AI ecosystem while leveraging its scientific and technical expertise. However, it cautions that there are no guarantees these initiatives will lead to successful transactions or revenue generation. SciSparc is also noted for its clinical-stage pharmaceutical developments through its subsidiary NeuroThera, which includes ongoing drug development programs related to cannabinoid pharmaceuticals.
Potential Positives
- Announcement of a strategic shift towards Agentic AI-powered technologies, indicating a forward-looking direction for the company's growth.
- Establishment of a Scientific Advisory Board for AI and Cybersecurity, which may enhance the company's expertise and credibility in these sectors.
- Focus on evaluating business opportunities in high-demand fields like cybersecurity and finance, aligning with trends in technology and market needs.
Potential Negatives
- The announcement of a strategic shift towards Agentic AI-powered technologies may indicate a lack of confidence in the company's existing pharmaceutical focus, potentially causing concern among investors about the stability of its core business.
- The press release contains numerous forward-looking statements with uncertainty surrounding the potential for successful execution of the new strategy, emphasizing a risk of not identifying viable opportunities in the Agentic AI field.
- There is no assurance provided that the company's new strategic focus will lead to any revenue-generating activities, which could lead to decreased investor confidence in its future profitability.
FAQ
What is SciSparc's new strategic focus?
SciSparc is shifting its strategic focus toward Agentic AI-powered technologies, particularly in cybersecurity and finance.
What does Agentic AI mean?
Agentic AI refers to artificial intelligence systems that autonomously plan and execute tasks to achieve specific objectives.
What are SciSparc's current drug development programs?
SciSparc, through NeuroThera, is developing programs for Tourette syndrome, Alzheimer's disease, and autism spectrum disorder.
What role does the Scientific Advisory Board have in SciSparc?
The Scientific Advisory Board for AI and Cybersecurity will help guide SciSparc's strategy in the Agentic AI market.
Is there any guarantee of success in SciSparc's strategic shift?
No, there is no assurance that SciSparc's efforts in Agentic AI will lead to commercial agreements or revenue.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SPRC Insider Trading Activity
$SPRC insiders have traded $SPRC stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SPRC stock by insiders over the last 6 months:
- ITSCHAK SHREM sold 462 shares for an estimated $4,620
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SPRC Hedge Fund Activity
We have seen 7 institutional investors add shares of $SPRC stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HRT FINANCIAL LP added 21,235 shares (+inf%) to their portfolio in Q2 2026, for an estimated $117,217
- JANE STREET GROUP, LLC added 16,496 shares (+inf%) to their portfolio in Q2 2026, for an estimated $91,057
- UBS GROUP AG added 1,372 shares (+43.6%) to their portfolio in Q2 2026, for an estimated $7,573
- JPMORGAN CHASE & CO added 211 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,164
- MORGAN STANLEY added 200 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,104
- STRATEGIC INVESTMENT SOLUTIONS, INC. /IL removed 133 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $734
- ROYAL BANK OF CANADA added 32 shares (+inf%) to their portfolio in Q2 2026, for an estimated $176
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
TEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies.
Building on its previously announced decision on July 27, 2026 to target the Agentic AI market and the announcement on August 26, 2026 of the establishment of its Scientific Advisory Board for AI and Cybersecurity, the Company intends to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem, with a focus on applications such as in cybersecurity and finance technologies.
Agentic AI refers to artificial intelligence systems designed to autonomously plan and execute tasks to achieve defined objectives. SciSparc aims to build on its scientific and technical foundation to identify opportunities in these markets and assess potential avenues for establishing its presence in the sector.
The Company will continue to evaluate opportunities in the field as it pursues its strategic shift. There can be no assurance that these efforts will result in any transaction, commercial agreement or revenue-generating activity for the Company.
About SciSparc Ltd. (Nasdaq: SPRC):
The Company, through its subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses its planned shift in strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies; its intention to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem; its aim to build on its scientific and technical foundation to identify opportunities in these markets and assess potential avenues for establishing its presence in the sector; and its plans to continue evaluating opportunities as it pursues its strategic shift. The Company may ultimately not identify any opportunities in the agentic AI field and may not ultimately realize the opportunities contemplated by its strategic shift into the field. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
[email protected]
Tel: +972-3-6167055